The Athletics Integrity Unit confirmed on Wednesday that long jumper Wang Jianan would not face any sanction after an investigation revealed an out-of-competition test contained traces of terbutaline — but was the result of “passive inhalation.”
Wang, 29, the 2022 men’s long jump world champion, was given a drug test by CHINADA, the China Anti-Doping Agency on November 1, 2024, which was positive for the substance. The AIU was later informed and began its own inquiry.
What followed was a year-long, extensive investigation, that included reviewing hospital surveillance footage. It was revealed that Wang was with a two family members — with one receiving nebulization treatment the day before and day of the drug test.
“The decision found that the Athlete had committed an anti-doping rule violation for the presence of a beta-2 agonist, Terbutaline, but that he bore No Fault or Negligence for the violation and therefore no period of ineligibility was imposed,” the AIU said in its final report.
In May, the AIU asked CHINADA for a number of additional pieces of evidence including outpatient records from the hospital and CCTV footage, which were apparently not included in CHINADA’s original case submission.
Wang was shown arriving at a hospital and in the waiting area in multiple camera angles in October 31, 2024 and November 1, 2024. The camera locations were along the exact route Wang and his family took inside of the facility and showed that Wang was in close contact with the family member where passive transfer of the drug could have occurred.
Meanwhile, in June and August, the AIU asked for more CCTV footage showing Wang inside and leaving the hospital on both days.
Terbutaline is typically used to treat asthma but is a banned beta-2 agonist that can be taken in high doses to increase muscle strength.
The AIU said it was satisfied with the result of the investigation while CHINADA announced the outcome of the inquiry on Monday.
